| Pegasys (pegylated interferon α -2a) / Roche |
| Completed | 4 | 43 | Europe | Peginterferon alfa-2a + ribavirin, Pegasys | Hospital Clinico Universitario San Cecilio | HIV Infections, Hepatitis C | 01/07 | 01/08 | | |
| Unknown status | 4 | 59 | Europe | Peg interferon + Ribavirin, Pegasys | University of Valencia, Hoffmann-La Roche | Chronic Hepatitis C, Co-Infection HIV-HCV | 04/08 | 12/08 | | |
NCT02761629: Efficacy and Safety of Peg-Interferon Alpha-2a Plus Ribavirin in Genotype 1 Chronic Hepatitis C Participants Co-Infected With Human Immunodeficiency Virus |
|
|
| Completed | 4 | 180 | RoW | Peg-Interferon Alpha-2A, Pegasys, Peg-IFN-Alpha-2A, Ribavirin | Hoffmann-La Roche | Hepatitis C, Chronic | 05/08 | 05/08 | | |
NCT00353418 / 2005-005506-23: A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Genotype 1 and Human Immunodeficiency Virus-1 (HIV-1) Co-infection |
|
|
| Completed | 4 | 415 | US | Peginterferon alfa-2a, Pegasys, Ribavirin, Copegus | Hoffmann-La Roche | Hepatitis C, Chronic | 04/09 | 04/09 | | |
NCT00470210 / 2006-005554-74: Peginterferon Alfa-2a, Ribavirin and Epoetin β in Coinfected Patients HCV/HIV Not Responding to Previous Treatment Regimens |
|
|
| Completed | 4 | 10 | Europe | Peginterferón alfa-2a (40 KD) (Pegasys®) 180 ug/week, Ribavirin (Copegus®) 1600 mg/day, Epoetin β (450 UI/kg/week) | Germans Trias i Pujol Hospital, Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia | Hepatitis C, HIV Infections | 06/09 | 06/09 | | |
| Completed | 4 | 71 | Europe | Pegylated interferon alfa-2a and Ribavirin, Pegasys, Copegus, Pegylated interferon alfa 2a and Ribavirin, Pegasis (TM), Copegus (TM) | Sociedad Andaluza de Enfermedades Infecciosas | Hepatitis C, Chronic, HIV Infections | 05/10 | 05/10 | | |
NCT00132210: Pegylated Interferon Therapy for Acute Hepatitis C Infection in HIV-infected Patients |
|
|
| Completed | 4 | 200 | Europe | pegylated interferon, Pegasys, PegIntron, Copegus, Rebetol | University Hospital, Bonn | Hepatitis C, HIV Infections | 06/10 | 06/10 | | |
NCT00845676: Treatment of Acute Hepatitis C Virus in HIV Co-Infection |
|
|
| Completed | 4 | 21 | US | Pegylated interferon alfa-2a + Ribavirin, Pegasys, PEG-IFN, RBV | University of California, San Francisco, California HIV/AIDS Research Program | Hepatitis C, Human Immunodeficiency Virus, HIV Infections | 12/10 | 12/13 | | |
2010-023245-30: Treatment with Peg-interferon alfa-2a and ribavirin in patients with hepatitis HCV-related, with or without HIV co-infection, and end stage renal disease on dialysis |
|
|
| Ongoing | 4 | 20 | Europe | Tablet, Solution for injection, COPEGUS*168CPR RIV 200MG, PEGASYS*SC SIR 0,5ML 180MCG+AG | ISTITUTO NAZIONALE DELLE MALATTIE INFETTIVE LAZZARO SPALLANZANI | Chonic hepatitis HCV-related | | | | |
CONTRA, NCT01684787: Study to Evaluate the Treatment for Chronic Hepatitis C With Normal Transaminases in HIV Positive Patients |
|
|
| Completed | 4 | 80 | Europe | Peginterferon alfa-2a + ribavirin in normal ALT, Pegasys + ribavirin, Peginterferon alfa-2a + ribavirin in elevated ALT | Miguel Santin | Chronic Hepatitis C | 05/11 | 06/11 | | |
| Completed | 4 | 6 | Europe | Pegylated interferon alpha-2a, Pegasys®, Roche, Ribavirin, Copegus®, Roche, Boceprevir, Victrelis®, MSD | Markus Peck-Radosavljevic, Medical University of Vienna | Hepatitis C, Chronic, HIV | 06/15 | 06/15 | | |
|
|
2005-002202-28: Hepatitis C virusdynamik og immunaktivering hos HCV/HIV-koinficerede patienter under behandling med pegyleret interferon a-2a og ribavirin |
|
|
| Completed | 4 | 20 | Europe | Pegasys, Copegus, Pegasys, Copegus | Rigshospitalet | HIV-infection and concomittant HCV-infection | | | | |
2006-001243-55: Open, multicenter, phase IV study to evaluate the safety and effectiveness of peginterferon alfa-2a (40 KD) associated with ribavirin for the treatment chronic hepatitis C with persistent normal ALT in HIV coinfected patients |
|
|
| Ongoing | 4 | 230 | Europe | Pegasys, Copegus, Pegasys, Copegus, Pegasys, Copegus | Miguel Santin Cerezales | Comparate the safety and effectivenes of the treatment with peginterferon alfa-2a in combination with ribavirin between HIV/HCV coinfected patients with persistent normal ALT levels versus HIV/HCV coinfected patients with high ALT levels | | | | |
